These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37548317)

  • 1. 'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.
    Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR
    Intern Med J; 2024 Apr; 54(4):559-567. PubMed ID: 37548317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibitors in the Management of Chronic Kidney Disease: An Expert Consensus.
    Jha V; Almeida A; Choudhury AR; Dutta AR; Khullar D; Gokulnath ; Anandh U; Khanna U; Kher V
    J Assoc Physicians India; 2022 Oct; 70(10):11-12. PubMed ID: 37355870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
    JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
    Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
    J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
    Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
    Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
    Siriyotha S; Lukkunaprasit T; Looareesuwan P; Nimitphong H; McKay GJ; Attia J; Thakkinstian A
    Cardiovasc Diabetol; 2022 Nov; 21(1):248. PubMed ID: 36397062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
    Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
    Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.